Retinoids modulate endothelial cell production of matrix-degrading proteases and tissue inhibitors of metalloproteinases (TIMP) - PubMed (original) (raw)

. 1994 May 6;269(18):13472-9.

Affiliations

• PMID: 8175780

Free article

Retinoids modulate endothelial cell production of matrix-degrading proteases and tissue inhibitors of metalloproteinases (TIMP)

S J Braunhut et al. J Biol Chem. 1994.

Free article

Abstract

We have previously reported that vitamin A inhibits the growth of capillary endothelial cells (EC) (Braunhut, S.J., and Palomares, M. (1991) Microvasc. Res. 41, 47-62). In this study, we have analyzed the effect of retinoids on the production and activity of enzymes involved in the proteolytic degradation of extracellular matrix (ECM) by EC. Substrate gel electrophoresis (zymography) revealed several major matrix metalloproteinases (MMP), of approximately 98-96, 72-68, and 46-45 kDa, whose activities were altered in their amounts in the conditioned media (CM) of EC following retinol or retinoic acid treatment when compared to amounts detected in CM of control cells. All of these gelatinases were inactivated by 1,10-phenanthroline, indicating that they were MMPs. MMP inhibitors (MMPI) were also present in these CM and were separated by gel filtration. Four distinct peaks of MMPIs were detected in the CM of EC. Chromatographic profiles indicated that an approximately 27-kDa MMPI was specifically increased in the CM of retinol-treated cells, whereas a 22-18.5-kDa MMPI was increased in CM derived from retinoic acid-treated cells. The MMPI synthesized by retinol-treated EC was immunologically related to tissue inhibitor of metalloproteinases, type 1 (TIMP-1), and the MMPI produced by retinoic acid-treated cells was related to TIMP-2, as indicated by biosynthetic labeling and immunoprecipitation studies as well as Western blot analysis. Therefore, retinol and retinoic acid treatment of EC differentially affects the types and activity of MMPs and MMPIs produced by the cells, distinct changes which are both correlated with growth inhibition.

PubMed Disclaimer

Similar articles

• Chondrocyte cultures express matrix metalloproteinase mRNA and immunoreactive protein; stromelysin-1 and 72 kDa gelatinase are localized in extracellular matrix vesicles.
  Schmitz JP, Dean DD, Schwartz Z, Cochran DL, Grant GM, Klebe RJ, Nakaya H, Boyan BD. Schmitz JP, et al. J Cell Biochem. 1996 Jun 1;61(3):375-91. doi: 10.1002/(SICI)1097-4644(19960601)61:3%3C375::AID-JCB5%3E3.0.CO;2-Q. J Cell Biochem. 1996. PMID: 8761942
• Soluble factor(s) released from neutrophils activates endothelial cell matrix metalloproteinase-2.
  Schwartz JD, Monea S, Marcus SG, Patel S, Eng K, Galloway AC, Mignatti P, Shamamian P. Schwartz JD, et al. J Surg Res. 1998 Apr;76(1):79-85. doi: 10.1006/jsre.1998.5294. J Surg Res. 1998. PMID: 9695744
• Collagenases and tissue inhibitors of metalloproteinases: a functional balance in tissue degradation.
  Reynolds JJ. Reynolds JJ. Oral Dis. 1996 Mar;2(1):70-6. doi: 10.1111/j.1601-0825.1996.tb00206.x. Oral Dis. 1996. PMID: 8957940 Review.
• MMP-2: expression, activation and inhibition.
  Corcoran ML, Hewitt RE, Kleiner DE Jr, Stetler-Stevenson WG. Corcoran ML, et al. Enzyme Protein. 1996;49(1-3):7-19. doi: 10.1159/000468613. Enzyme Protein. 1996. PMID: 8796994 Review.

Cited by

• All-trans-retinoic acid suppresses matrix metalloproteinase activity and increases collagen synthesis in diabetic human skin in organ culture.
  Lateef H, Stevens MJ, Varani J. Lateef H, et al. Am J Pathol. 2004 Jul;165(1):167-74. doi: 10.1016/S0002-9440(10)63285-3. Am J Pathol. 2004. PMID: 15215172 Free PMC article.
• Tuberculosis and its incidence, special nature, and relationship with chronic obstructive pulmonary disease.
  Chakrabarti B, Calverley PM, Davies PD. Chakrabarti B, et al. Int J Chron Obstruct Pulmon Dis. 2007;2(3):263-72. Int J Chron Obstruct Pulmon Dis. 2007. PMID: 18229564 Free PMC article. Review.
• Effects of a synthetic retinoid on skin structure, matrix metalloproteinases, and procollagen in healthy and high-risk subjects with diabetes.
  Zeng W, Tahrani A, Shakher J, Varani J, Hughes S, Dubb K, Stevens MJ. Zeng W, et al. J Diabetes Complications. 2011 Nov-Dec;25(6):398-404. doi: 10.1016/j.jdiacomp.2011.10.002. Epub 2011 Nov 4. J Diabetes Complications. 2011. PMID: 22055260 Free PMC article.
• PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis.
  Panigrahy D, Singer S, Shen LQ, Butterfield CE, Freedman DA, Chen EJ, Moses MA, Kilroy S, Duensing S, Fletcher C, Fletcher JA, Hlatky L, Hahnfeldt P, Folkman J, Kaipainen A. Panigrahy D, et al. J Clin Invest. 2002 Oct;110(7):923-32. doi: 10.1172/JCI15634. J Clin Invest. 2002. PMID: 12370270 Free PMC article.
• Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways.
  Arbiser JL, Moses MA, Fernandez CA, Ghiso N, Cao Y, Klauber N, Frank D, Brownlee M, Flynn E, Parangi S, Byers HR, Folkman J. Arbiser JL, et al. Proc Natl Acad Sci U S A. 1997 Feb 4;94(3):861-6. doi: 10.1073/pnas.94.3.861. Proc Natl Acad Sci U S A. 1997. PMID: 9023347 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal